PDCD1 and neoplasm: Although it is very evident that sufficient tumor antigenicity is required for a successful anti-PD1 treatment, so far, very few studies have been conducted to investigate the potential reasons for reduced efficacy to anti-PD1 treatment in the younger patients, mainly focusing on TMB and immunoediting mechanisms.